Bombay HC orders Sun Pharma to cough up pending wages
- Tata Motors stops production of Indica, Indigo CS
- Healthcare, energy farm, smart cities seen boosting 5G demand
- 5G to offer $27 billion opportunity for India by 2026: Ericsson
- Hyundai to hike vehicle prices by up to 2% from June, no change in new Creta prices
- US eyes India’s dairy market, seeks to pull sops to textiles industry
Mumbai: The Bombay high court on Wednesday rejected a writ petition filed by Sun Pharmaceutical Industries Ltd against an order of the Maharashtra Industrial Court asking the company to pay pending wages of 86 sales representatives who joined the company after its merger with Ranbaxy Laboratories Ltd.
The Federation of Medical and Sales Representatives’ Associations of India had filed a lawsuit against Sun Pharma in June, alleging that the company was engaging in unfair labour practices after it withheld salary and expenses of the sales representatives since May.
An industrial court said in its verdict in June that Sun Pharma had engaged in unfair labour practices under the Maharashtra Recognition of Trade Unions and Prevention of Unfair Labour Practices Act.
Justice R. M. Sawant of the Bombay high court on Wednesday directed Sun Pharma to pay the pending salary and expenses of all the medical sales representatives.
A Sun Pharma spokesperson declined to comment.
Sun Pharma, which bought Ranbaxy last year for $3.5 billion, has been facing protests after it allegedly transferred and demoted some employees of the acquired company.